2Johann D, Pitout D, Gregson DB, et al. Detection of pseud om onas aeruginosa producing metallo β lactamases in a large centralized laboratory. J Clin Microbiol, 2005, 43(7):3129- 3135.
5Majumdar S, Kirby A, Berry N, et al. An outbreak of imipenem-resistant Pseudomonas aeruginosa, in an intensive care unit [ J ]. J Hosp Infect,2004,58(2) :160-161.
6Quale J, Bratu S, Gupta J, et al. Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomomas aeruginosa clinical isolates [ J ]. Antimicrob Agents Chemother, 2006,50 (5) :1633-1641.
7Sanchez A, Salso S, Culebras E, et al. Carbapenem resistance determined by metalloenzymes in clinical isolates of Pseudomonas aeruginosa[ J]. Rev Esp Quimioter,2004,17(4) :336-340.
8Pirnay J P, De Vos D, Mossialos D, et al Analysis of the Pseudomonas aeruginosa OprD gene from clinical and environmental isolates [ J ]. Environ Microbiol,2002,4 ( 12 ) :872-882.
9Garciade L J, Navarro D, Gimeno C. Penetration of meropenem in gram-negative bacilli. Differences in activity with imipenem [ J]. Enferm Infect Microbiol Clin, 1997,15 (9) : 14-19.
10Ochs M M, McCusker M P, Bains M,et al. Negative regulation of the Pseudomonas aeruginosa outer membrane porin OprD selective for imipenem and basic amino acids [ J ]. Antimicrob Agents Chemother, 1999,43 (5) : 1085-1090.
8Clinical and Laboratory Standards Institute. Performance stan- dards for antimicrobial susceptibility testing. Sixteenth Informa- tional Supplement, 2009, MIO0-SI9.
9Falagas ME, Koletsi PK, Bliziotis IA. The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J Med Microbiol, 2006, 55:1619-1629.
10Falagas ME, Karageorgopoulos DE. Pandrug resistance (PDR), extensive drug resistance (XDR), and muhidrug resistance (MDR) among Gram-negative bacilli: need for international harmonization in terminology. Clin Infect Dis, 2008, 46: 1121-1122; author reply 1122.
